Cargando…
Assessment of artemisinin tolerance in Plasmodium falciparum clinical isolates in children with uncomplicated malaria in Ghana
BACKGROUND: Artemisinin-based combination therapy (ACT) is the first-line treatment for uncomplicated malaria in Ghana. Artemisinin (ART) tolerance in Plasmodium falciparum has arisen in Southeast Asia and recently, in parts of East Africa. This is ascribed to the survival of ring-stage parasites po...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9938975/ https://www.ncbi.nlm.nih.gov/pubmed/36803541 http://dx.doi.org/10.1186/s12936-023-04482-w |
_version_ | 1784890745672433664 |
---|---|
author | Ahorhorlu, Samuel Yao Quashie, Neils Ben Jensen, Rasmus Weisel Kudzi, William Nartey, Edmund Tetteh Duah-Quashie, Nancy Odurowah Zoiku, Felix Dzudzor, Bartholomew Wang, Christian William Hansson, Helle Alifrangis, Michael Adjei, George Obeng |
author_facet | Ahorhorlu, Samuel Yao Quashie, Neils Ben Jensen, Rasmus Weisel Kudzi, William Nartey, Edmund Tetteh Duah-Quashie, Nancy Odurowah Zoiku, Felix Dzudzor, Bartholomew Wang, Christian William Hansson, Helle Alifrangis, Michael Adjei, George Obeng |
author_sort | Ahorhorlu, Samuel Yao |
collection | PubMed |
description | BACKGROUND: Artemisinin-based combination therapy (ACT) is the first-line treatment for uncomplicated malaria in Ghana. Artemisinin (ART) tolerance in Plasmodium falciparum has arisen in Southeast Asia and recently, in parts of East Africa. This is ascribed to the survival of ring-stage parasites post treatment. The present study sought to assess and characterize correlates of potential ART tolerance based on post-treatment parasite clearance, ex vivo and in vitro drug sensitivity, and molecular markers of drug resistance in P. falciparum isolates from children with uncomplicated malaria in Ghana. METHODS: Six months to fourteen years old children presenting with acute uncomplicated malaria (n = 115) were enrolled in two hospitals and a Health Centre in Ghana’s Greater Accra region and treated with artemether-lumefantrine (AL) according to body weight. Pre- and post-treatment parasitaemia (day 0 and day 3) was confirmed by microscopy. The ex vivo ring-stage survival assay (RSA) was used to detect percent ring survival while the 72 h SYBR Green I assay was used to measure the 50% inhibition concentration (IC(50s)) of ART and its derivatives and partner drugs. Genetic markers of drug tolerance /resistance were evaluated using selective whole genome sequencing. RESULTS: Of the total of 115 participants, 85 were successfully followed up on day 3 post-treatment and 2/85 (2.4%) had parasitaemia. The IC(50) values of ART, artesunate (AS), artemether (AM), dihydroartemisinin (DHA), amodiaquine (AQ), and lumefantrine (LUM) were not indicative of drug tolerance. However, 7/90 (7.8%) pre-treatment isolates had > 10% ring survival rates against DHA. Of the four isolates (2 RSA positive and 2 RSA negative) with high genomic coverage, P. falciparum (Pf) kelch 13 K188* and Pfcoronin V424I mutations were only present in the two RSA positive isolates with > 10% ring survival rates. CONCLUSIONS: The observed low proportion of participants with day-3 post-treatment parasitaemia is consistent with rapid ART clearance. However, the increased rates of survival observed in the ex vivo RSA against DHA, maybe a pointer of an early start of ART tolerance. Furthermore, the role of two novel mutations in PfK13 and Pfcoronin genes, harboured by the two RSA positive isolates that had high ring survival in the present study, remains to be elucidated. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12936-023-04482-w. |
format | Online Article Text |
id | pubmed-9938975 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-99389752023-02-20 Assessment of artemisinin tolerance in Plasmodium falciparum clinical isolates in children with uncomplicated malaria in Ghana Ahorhorlu, Samuel Yao Quashie, Neils Ben Jensen, Rasmus Weisel Kudzi, William Nartey, Edmund Tetteh Duah-Quashie, Nancy Odurowah Zoiku, Felix Dzudzor, Bartholomew Wang, Christian William Hansson, Helle Alifrangis, Michael Adjei, George Obeng Malar J Research BACKGROUND: Artemisinin-based combination therapy (ACT) is the first-line treatment for uncomplicated malaria in Ghana. Artemisinin (ART) tolerance in Plasmodium falciparum has arisen in Southeast Asia and recently, in parts of East Africa. This is ascribed to the survival of ring-stage parasites post treatment. The present study sought to assess and characterize correlates of potential ART tolerance based on post-treatment parasite clearance, ex vivo and in vitro drug sensitivity, and molecular markers of drug resistance in P. falciparum isolates from children with uncomplicated malaria in Ghana. METHODS: Six months to fourteen years old children presenting with acute uncomplicated malaria (n = 115) were enrolled in two hospitals and a Health Centre in Ghana’s Greater Accra region and treated with artemether-lumefantrine (AL) according to body weight. Pre- and post-treatment parasitaemia (day 0 and day 3) was confirmed by microscopy. The ex vivo ring-stage survival assay (RSA) was used to detect percent ring survival while the 72 h SYBR Green I assay was used to measure the 50% inhibition concentration (IC(50s)) of ART and its derivatives and partner drugs. Genetic markers of drug tolerance /resistance were evaluated using selective whole genome sequencing. RESULTS: Of the total of 115 participants, 85 were successfully followed up on day 3 post-treatment and 2/85 (2.4%) had parasitaemia. The IC(50) values of ART, artesunate (AS), artemether (AM), dihydroartemisinin (DHA), amodiaquine (AQ), and lumefantrine (LUM) were not indicative of drug tolerance. However, 7/90 (7.8%) pre-treatment isolates had > 10% ring survival rates against DHA. Of the four isolates (2 RSA positive and 2 RSA negative) with high genomic coverage, P. falciparum (Pf) kelch 13 K188* and Pfcoronin V424I mutations were only present in the two RSA positive isolates with > 10% ring survival rates. CONCLUSIONS: The observed low proportion of participants with day-3 post-treatment parasitaemia is consistent with rapid ART clearance. However, the increased rates of survival observed in the ex vivo RSA against DHA, maybe a pointer of an early start of ART tolerance. Furthermore, the role of two novel mutations in PfK13 and Pfcoronin genes, harboured by the two RSA positive isolates that had high ring survival in the present study, remains to be elucidated. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12936-023-04482-w. BioMed Central 2023-02-19 /pmc/articles/PMC9938975/ /pubmed/36803541 http://dx.doi.org/10.1186/s12936-023-04482-w Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Ahorhorlu, Samuel Yao Quashie, Neils Ben Jensen, Rasmus Weisel Kudzi, William Nartey, Edmund Tetteh Duah-Quashie, Nancy Odurowah Zoiku, Felix Dzudzor, Bartholomew Wang, Christian William Hansson, Helle Alifrangis, Michael Adjei, George Obeng Assessment of artemisinin tolerance in Plasmodium falciparum clinical isolates in children with uncomplicated malaria in Ghana |
title | Assessment of artemisinin tolerance in Plasmodium falciparum clinical isolates in children with uncomplicated malaria in Ghana |
title_full | Assessment of artemisinin tolerance in Plasmodium falciparum clinical isolates in children with uncomplicated malaria in Ghana |
title_fullStr | Assessment of artemisinin tolerance in Plasmodium falciparum clinical isolates in children with uncomplicated malaria in Ghana |
title_full_unstemmed | Assessment of artemisinin tolerance in Plasmodium falciparum clinical isolates in children with uncomplicated malaria in Ghana |
title_short | Assessment of artemisinin tolerance in Plasmodium falciparum clinical isolates in children with uncomplicated malaria in Ghana |
title_sort | assessment of artemisinin tolerance in plasmodium falciparum clinical isolates in children with uncomplicated malaria in ghana |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9938975/ https://www.ncbi.nlm.nih.gov/pubmed/36803541 http://dx.doi.org/10.1186/s12936-023-04482-w |
work_keys_str_mv | AT ahorhorlusamuelyao assessmentofartemisinintoleranceinplasmodiumfalciparumclinicalisolatesinchildrenwithuncomplicatedmalariainghana AT quashieneilsben assessmentofartemisinintoleranceinplasmodiumfalciparumclinicalisolatesinchildrenwithuncomplicatedmalariainghana AT jensenrasmusweisel assessmentofartemisinintoleranceinplasmodiumfalciparumclinicalisolatesinchildrenwithuncomplicatedmalariainghana AT kudziwilliam assessmentofartemisinintoleranceinplasmodiumfalciparumclinicalisolatesinchildrenwithuncomplicatedmalariainghana AT narteyedmundtetteh assessmentofartemisinintoleranceinplasmodiumfalciparumclinicalisolatesinchildrenwithuncomplicatedmalariainghana AT duahquashienancyodurowah assessmentofartemisinintoleranceinplasmodiumfalciparumclinicalisolatesinchildrenwithuncomplicatedmalariainghana AT zoikufelix assessmentofartemisinintoleranceinplasmodiumfalciparumclinicalisolatesinchildrenwithuncomplicatedmalariainghana AT dzudzorbartholomew assessmentofartemisinintoleranceinplasmodiumfalciparumclinicalisolatesinchildrenwithuncomplicatedmalariainghana AT wangchristianwilliam assessmentofartemisinintoleranceinplasmodiumfalciparumclinicalisolatesinchildrenwithuncomplicatedmalariainghana AT hanssonhelle assessmentofartemisinintoleranceinplasmodiumfalciparumclinicalisolatesinchildrenwithuncomplicatedmalariainghana AT alifrangismichael assessmentofartemisinintoleranceinplasmodiumfalciparumclinicalisolatesinchildrenwithuncomplicatedmalariainghana AT adjeigeorgeobeng assessmentofartemisinintoleranceinplasmodiumfalciparumclinicalisolatesinchildrenwithuncomplicatedmalariainghana |